Home▸Cold, Flu & RSV▸Paxlovid Mechanism & Rebound Phenomenon Simulator

🤧 Paxlovid Mechanism & Rebound Phenomenon Simulator

This simulator illustrates how nirmatrelvir/ritonavir works to inhibit viral protease in cases of COVID-19, and explains the mechanism behind symptom rebound after completing a course of treatment.

Cold, Flu & RSV2DModerate60 FPS
paxlovid-mechanism-rebound-simulator ↗ Open standalone

Nirmatrelvir Blocks the Main Viral Protease

A short placeholder sentence on protease inhibition mechanism.

  • 3CLpro: Target enzyme (Placeholder short note)
  • Covalent: Inhibitor type (Placeholder short note)
  • Active site: Binding site (Placeholder short note)
  • Ritonavir: Booster drug (Placeholder short note)

How nirmatrelvir stops the protease

Placeholder sentence describing active-site binding and polyprotein cleavage blockade.

Fixed Five-Day Dosing Schedule

A short placeholder sentence on the standard dosing regimen.

  • 5 days: Course length (Placeholder short note)
  • 2x daily: Dosing (Placeholder short note)
  • ≤5 days: Start window (Placeholder short note)
  • CYP3A4 boost: Ritonavir role (Placeholder short note)

Why ritonavir boosting matters

Placeholder sentence describing CYP3A4 inhibition extending nirmatrelvir exposure.

Rapid Drop in Viral Load During Therapy

A short placeholder sentence on suppression kinetics.

  • ~3 logs: Load drop (Placeholder short note)
  • Day 1-3: Onset (Placeholder short note)
  • Faster drop: Adherence effect (Placeholder short note)
  • ~1-2 days: Symptom lag (Placeholder short note)

Replication halted, load falls

Placeholder sentence describing rapid decline in detectable viral RNA.

Viral and Symptom Rebound After Stopping

A short placeholder sentence on the rebound mechanism.

  • Day 7-9: Rebound window (Placeholder short note)
  • ~10-20%: Reported rate (Placeholder short note)
  • Incomplete clearance: Cause theory (Placeholder short note)
  • Not routine: Retreatment (Placeholder short note)

Why rebound happens

Placeholder sentence describing residual virus reemerging after drug clearance.

Placeholder short callout about rebound not requiring a second antiviral course.

Final Clearance and Symptom Resolution

A short placeholder sentence on eventual full recovery.

  • Day 10+: Resolution (Placeholder short note)
  • Adaptive clearance: Immune role (Placeholder short note)
  • Until negative: Isolation (Placeholder short note)
  • Full recovery: Outcome (Placeholder short note)

Immune system finishes the job

Placeholder sentence describing adaptive immunity clearing residual virus.

⚙ Under the hood

This simulator illustrates how nirmatrelvir/ritonavir works to inhibit viral protease in cases of COVID-19, and explains the mechanism behind symptom rebound after completing a course of treatment.

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install

What did you find?

Add reproduction steps (optional)